Immune cells in lung disease and how they could guide immunotherapy
Official title: Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease
Run by Université Catholique de Louvain · NCT07384897 · Data updated 2026-11-12
This project sees if immune cell profiling from blood can explain why people with lung cancer, sarcoidosis, or COPD respond differently to immunotherapy or develop chronic lung inflammation.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | Any age to 80 Years |
| Sex | All |
| Enrollment | 425 (estimated) |
| Sponsor | Université Catholique de Louvain Academic / other |
| Drugs / interventions | prednisone, immunotherapy |
| Locations | 1 site (Brussels) |
| Status | Recruiting |
| Started | February 17, 2025 |
| Main results expected | December 1, 2030 |
| Study ends | February 17, 2032 |
| Registry record updated | February 3, 2026 |
| Trial ID | NCT07384897 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults with lung cancer or precancerous lung lesions, untreated patients with sarcoidosis or COPD, eligible children with genetically confirmed CGD (≥10 kg), healthy control volunteers, and adults scheduled for orthopedic surgery who can provide bone marrow, provided they can give informed consent and are not on high-dose steroids or immunosuppressants.
✕Probably not a fit
Patients currently on systemic immunosuppressive therapy or high-dose corticosteroids, those with an acute infection, or those unwilling/unable to consent are excluded and are unlikely to benefit from this research-focused protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will collect peripheral blood (and in some cases bone marrow collected during planned orthopedic surgery) to profile immune cells from people with lung cancer, precancerous lung lesions, sarcoidosis, COPD, and from healthy controls. The study excludes people with acute infection, those on high-dose systemic corticosteroids (>10 mg/day prednisone equivalent), or on chronic immunosuppressive therapy. Immune cell types and signatures will be compared between disease groups and controls to identify patterns linked to inflammation, cancer progression, or resistance to immunotherapy. The findings aim to generate biomarkers and hypotheses that could guide more personalized treatments in future trials.
Why it matters
Potential benefit: If successful, this work could identify immune-cell patterns that help doctors choose or design more effective, personalized immunotherapies and treatments for lung diseases.
How similar studies have gone: Similar immune-profiling studies have shown promise in identifying biomarkers of immunotherapy response and inflammation but have not yet produced universally reliable clinical tests.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of lung cancer * Presence of precancerous lung lesions * Patients with a chronic inflammatory lung disease (sarcoidosis or chronic obstructive pulmonary disease \[COPD\]) prior to any treatment * Control group: individuals without known lung disease * Children and adolescents weighing ≥ 10 kg with genetically confirmed chronic granulomatous disease (CGD) * Adults scheduled to undergo orthopedic surgery during which a bone marrow sample will be collected Exclusion Criteria: * Systemic corticosteroid therapy \> 10 mg/day prednisone (or equivalent) * Acute infection at the time of inclusion * Refusal or inability to provide informed consent (or assent, when applicable) * Chronic inflammatory lung disease currently treated with immunosuppressive therapy
Where it's running
-
Cliniques universitaires saint Luc
Brussels, Belgium Recruiting
Study contacts
- Study coordinator: Frank Aboubakar Nana, MD; PhD
- Email: frank.aboubakar@saintluc.uclouvain.be
- Phone: 0032 2 764 85 19
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Boosting lung cancer screening for patients seen in the emergency department
This project will test whether giving eligible emergency department patients a facilitated referral plus text reminders helps more people get lung cancer screening.
-
Flutter therapy added to chest physiotherapy after CABG in COPD patients
This study tests whether adding Flutter therapy to standard chest physiotherapy helps post-CABG patients with mild-to-moderate COPD improve breathing more than chest physiotherapy alone.
-
TPB-based cadence exercise and breathing training for COPD patients
A TPB-based program tests whether breathing training, cadence-guided walking, or both can improve lung function, exercise capacity, and quality of life in adults with COPD.
-
Risk-based lung cancer screening in COPD patients using ML and clinical models
This study tests whether a PLCOm2012 risk model plus a machine learning model can spot COPD patients at high risk for lung cancer to see if they benefit from low-dose CT screening.
-
AI-Personalized Discharge Education After Lung Cancer Surgery
This study tests whether an AI-generated, personalized discharge guide helps patients recover better after lung cancer surgery compared with standard discharge education.
-
Next Generation Delivery System (NGDS) for SBRT in thorax and upper abdomen
A study tests a new machine to deliver SBRT more quickly and comfortably for adults with thoracic or upper abdominal cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.